Background: Thrombocytosis can accompany various cancers including lung cancer. This finding has recently been suggested to indicate poor prognosis. Objectives and Methods: We retrospectively examined the clinical records of 611 patients with lung cancer to investigate whether there is a correlation between thrombocytosis, other clinicopathologic factors, and survival Results: Ninety-eight of the patients (16%) manifested thrombocytosis at the time of their first evaluation at our hospital. Thrombocytosis and age (p = 0.0006) and thrombocytosis and performance status (p = 0.0002) are significantly correlated, but thrombocytosis is not related to gender, tumor histology, clinical stage, or serum lactate dehydrogenase concentrations. Survival is significantly shorter in patients with thrombocytosis: [median survival time (MST) 7.5 months; n = 98] than without thrombocytosis (MST 10.1 months; n = 513; p = 0.0029). Multivariate analysis of prognostic factors using the Cox proportional hazards model indicated that thrombocytosis had independent prognostic significance. Conclusion: Thrombocytosis at the first patient evaluation is an independent prognostic factor in lung cancer.

Keywords:
Thrombocytosis, Poor prognosis, Multivariate analysis of prognostic factors, Lung cancer, Platelet count
1.
Milus AJ, Schafer AJ: Thrombocytosis and thrombocythemia. Hematol Oncol Clin North Am 1990;4:157–158.
2.
Costatini V, Zacharaski L, Moritz T, Edwards R: The platelet count in carcinoma of the lung and colon. Thromb Haemost 1990:64:501–505.
3.
Silvis SE, Turkbas N, Doscherrholmen A: Thrombocytosis in patients with lung cancer. JAMA 1979;211:1852–1853.
4.
Diehl WL, Mandelbaum I: The significance of thrombocytosis in patients with carcinoma of the lung. Surg Gynecol Obstet 1983;156:187–188.
5.
Gislason T, Nou E: Sedimentation rate, leucocytes, platelet count and haemoglobin in bronchial carcinoma: An epidemiological study. Eur J Respir Dis 1985;66:141–146.
6.
Engan T, Hannisdal E: Blood analysis as prognostic factors in primary lung cancer. Acta Oncol 1990;29:151–154.
7.
Pedorsen LM, Milman N: Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996;9:1826–1830.
8.
Symbas NP, Townsend MF, El GR, Keane TE, Graham SD, Petros JA: Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BUJ Int 2000;86:203–207.
9.
Hernandez E, Lavine M, Dunton CJ, Gracely E, Parker J: Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992;69:2975–2977.
10.
Rodriguez GC, Clarke PD, Soper JT, Berchuck A, Synan I, Dodge RK: The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Obstet Gynecol 1994;83:445–448.
11.
Lopes A, Daras V, Cross PA, Robertson G, Beynon G, Monaghan JM: Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer 1994;74:90–92.
12.
Chalas E, Welshinger M, Engellener W, Chumas J, Barbrieri R, Mann WJ: The clinical significance of thrombocytosis in women presenting with a pelvic mass. Am J Obstet Gynecol 1992;166:974–977.
13.
Ziemet AG, Marth C, Muller-Holzner E, Daxenbichler G, Dapunt O: Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1994:170:549–554.
14.
Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsumu M, Satomi T: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002;9:287–291.
15.
Suzuki A, Takahashi T, Nakamura K, Tsuyuoka R, Okuno Y, Enomoto T, Fukumoto M, Imaru H: Thrombocytosis in patients with tumors producing colony-stimulating factor. Blood 1993;80:2052–2059.
16.
Tefferi A, Ho TC, Ahmann GJ, Katzmann JA, Greipp PR: Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med 1994;97:374–378.
17.
Alexandrakis MG, Passam FH, Perisinakis K, Ganotakis E, Margantinis G, Kyriakou DS, Bouros D: Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. Respir Med 2002;96:553–558.
18.
Lidor YJ, Xu FJ, Martinez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC Jr: Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res 1993;207:332–339.
19.
Gucer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, Petru E, Winter R: Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol 1998;70:210–214.
20.
Scholz H, Petru E, Gucer F, Haas J, Tamussino K, Winter R: Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res 2000;20:3983–3986.
21.
Honn K, Tang DG, Crissman JD: Platelet and cancer metastasis: A causal relationship? Cancer Metast Rev 1992;11:325–351.
22.
Karpatkin S, Pearlstein E: Role of platelets in tumor cell metastasis. Ann Intern Med 1981;95:636–641.
23.
Nieswandt B, Hafner M, Echtenacher B, Mannel DN: Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295–1300.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.